Price
$176.86+18.67%Social Signal Score
Analyst Ratings
34 analystsRevenue
$5.27B+80.49%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas E. Polen Jr.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 60,000
- Beta
- 0.28
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 1.86
Financials
Revenue
$5.27B+80.5%Net Income
$696.00M+23.8%EBITDA
$1.57B+49.9%Free Cash Flow
$1.16B+470.6%EPS (diluted)
$2.54-1.6%Shares Outstanding (diluted)
274.05M+25.9%Operating Expenses
$1.51BCash & Debt
$733.00MReturn of Capital
$469.00MRevenue by Segment (annual)
$21.84BDividend per Share
$1.06Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $19.46B | $1.15B | $4.11 |
| 2025 | $21.84B | $1.68B | $5.84 |
| 2024 | $20.18B | $1.71B | $5.88 |
| 2023 | $19.37B | $1.48B | $4.97 |
| 2022 | $18.87B | $1.78B | $5.93 |
| 2021 | $19.13B | $2.09B | $6.92 |
| 2020 | $16.07B | $874.00M | $2.75 |
| 2019 | $17.29B | $1.23B | $3.96 |
| 2018 | $15.98B | $311.00M | $0.62 |
| 2017 | $12.09B | $1.10B | $4.70 |
| 2016 | $12.48B | $976.00M | $4.59 |
| 2015 | $10.28B | $695.00M | $3.43 |
| 2014 | $8.45B | $1.19B | $6.13 |
| 2013 | $8.05B | $1.29B | $6.63 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BDX's reported EPS growth of -3.6% a year over 13 years.
- EPS in 5 years
- $3.43
- Implied price
- $150.74
- Return from $212.78
- -6.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $74.94 — -64.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 30 | 37 | 44 | 51 | 58 |
|---|---|---|---|---|---|
| -13.6% | -22.5% | -19.2% | -16.3% | -13.8% | -11.6% |
| -8.6% | -18.0% | -14.5% | -11.5% | -8.9% | -6.5% |
| -3.6% | -13.5% | -9.8% | -6.7% | -3.9% | -1.4% |
| 1.4% | -9.1% | -5.2% | -1.8% | 1.1% | 3.8% |
| 6.4% | -4.6% | -0.5% | 3.0% | 6.1% | 8.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (43)
- Newsdefenseworld.net·1d ago·Negative
3,205 Shares of Becton, Dickinson and Company $BDX Purchased by Banco Santander S.A. Banco Santander S.A. purchased a new position in Becton, Dickinson and Company (NYSE: BDX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,205 shares of the medical instruments supplier's stock, valued at approximately $574,000. Several other institutional investors
View source ↗ - Newsprnewswire.com·3d ago·Positive
… network today makes approximately 6.5 million medical devices annually FRANKLIN LAKES, N.J., Nov. 19, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today celebrates the 85th anniversary of its manufacturing site in Glens Falls, New York, highlighting its generations-long role in strengthening American healthcare resilience and partnership in the communities where it operates.
View source ↗ - Newsprnewswire.com·3d ago·Positive
…dership and critical role strengthening America's healthcare resilience FRANKLIN LAKES, N.J., Nov. 19, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has been named to TIME's 2027 list of America's Top Manufacturers based on an independent evaluation of the company's financial performance, innovation capacity and employment.
View source ↗ - Newsprnewswire.com·12d ago·Neutral
BD to Host Investor Day on December 10, 2026 FRANKLIN LAKES, N.J., Nov. 10, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host an Investor Day for institutional investors and financial analysts on Thursday, December 10, 2026, in New York, NY.
View source ↗ - Newszacks.com·16d ago·Neutral
3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility BDX, COR and UNF recently hiked dividends, offering investors steady income opportunities as market volatility, inflation and economic uncertainty persist.
View source ↗ - Newsmarketbeat.com·16d ago·Negative
Becton, Dickinson and Company Q4 Earnings Call Highlights Becton, Dickinson and Company NYSE: BDX reported higher fiscal fourth-quarter revenue and adjusted earnings as demand for patient monitoring, biologic drug delivery and other products helped offset a difficult comparison for its Alaris infusion platform.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Becton, Dickinson and Company (BDX) Q4 2026 Earnings Call Transcript Becton, Dickinson and Company (BDX) Q4 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Positive
BDX Stock Down in Pre-Market Despite Q4 Earnings & Revenue Beat BD stock lost 6.4% in pre-market trading despite Q4 earnings and revenue beat, as its subdued fiscal 2027 revenue growth outlook raises investor concerns.
View source ↗ - News (RSS)seekingalpha·17d ago·Neutral
Becton, Dickinson and Company 2026 Q4 - Results - Earnings Call Presentation
View source ↗ - Newszacks.com·17d ago·Positive
Becton Dickinson (BDX) Surpasses Q4 Earnings and Revenue Estimates Becton Dickinson (BDX) came out with quarterly earnings of $4.15 per share, beating the Zacks Consensus Estimate of $4.06 per share. This compares to earnings of $3.96 per share a year ago.
View source ↗ - Newsprnewswire.com·17d ago·Neutral
…e cash flow increased 42.5% to $2.9 billion Company issues FY27 guidance FRANKLIN LAKES, N.J., Nov. 5, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 fourth quarter and full year, which ended September 30, 2026.
View source ↗ - Newsprnewswire.com·17d ago·Negative
BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases FRANKLIN LAKES, N.J., Nov. 5, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has declared a quarterly dividend of $1.06 per common share, an increase of 1.0% from the previous quarter.
View source ↗ - Newsprnewswire.com·18d ago·Positive
BD Names Bridget Bagnato Worldwide President of Peripheral Intervention FRANKLIN LAKES, N.J., Nov. 4, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Bridget Bagnato has been appointed worldwide president of its Peripheral Intervention business unit, effective November 16.
View source ↗ - Newszacks.com·19d ago·Neutral
BDX Gears Up to Report Q4 Results: How to Play the Stock? BD heads into Q4 earnings with expectations of higher profits despite lower revenues, backed by strength in Interventional, Medical Essentials and Biologics.
View source ↗ - Newszacks.com·19d ago·Negative
Becton Dickinson (BDX) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates Besides Wall Street's top-and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
View source ↗ - Newsprnewswire.com·25d ago·Neutral
BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options The launch of the Liverty™ TIPS Stent Graft gives physicians flexibility to tailor treatment for patients. FRANKLIN LAKES, N.J.
View source ↗ - Newsseekingalpha.com·27d ago·Positive
First Eagle U.S. Value Fund Q3 2026 Portfolio Review U.S. Fund A Shares (without sales charge) posted a return of 4.36% in third-quarter 2026. The US Fund outperformed the S&P 500 Index in the period. Shares of Meta performed well following the strong reception of Muse, its personalized AI assistance app.
View source ↗ - Newszacks.com·31d ago·Positive
BDX Stock Gains 25.5% in Six Months: What's Behind the Rally? BD's 25.5% rally reflects stronger execution, portfolio reshaping, product innovation and U.S. manufacturing investments despite tariffs and cost pressures.
View source ↗ - News (RSS)seekingalpha·34d ago·Negative
Becton, Dickinson: Fundamentals Remain Solid, Trades Near Fair Value (Rating Downgrade)
View source ↗ - Newszacks.com·38d ago·Positive
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients BDX's Revello stent shows strong nine-month AGILITY trial results, with high vessel patency and low failure rates, boosting its peripheral vascular prospects.
View source ↗ - Newszacks.com·44d ago·Neutral
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report? Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newsprnewswire.com·45d ago·Neutral
BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026 FRANKLIN LAKES, N.J., Oct. 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.
View source ↗ - Newszacks.com·46d ago·Neutral
BDX Expands U.S. Manufacturing With $19B Healthcare Investment BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.
View source ↗ - Newsprnewswire.com·46d ago·Positive
BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease. FRANKLIN LAKES, N.J.
View source ↗ - News (Marketaux)gurufocus.com·47d ago·Positive
Becton Dickinson (BDX) to Invest $3 Billion in U.S. Medical Supply Production On October 06, 2026, Becton Dickinson & [+320 characters]
View source ↗ - Newsprnewswire.com·47d ago·Neutral
BD Appoints Ferass Abuzaina as Worldwide President of Surgery FRANKLIN LAKES, N.J., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Ferass Abuzaina has been named worldwide president of the Surgery business unit at BD, effective immediately.
View source ↗ - Newsprnewswire.com·47d ago·Neutral
…medical consumables used in approximately 90% of U.S. hospital visits FRANKLIN LAKES, N.J., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), one of the world's leading medical technology companies and the nation's largest manufacturer of essential medical consumables, today announced a landmark partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for essential medical consumables relied on by clinician…
View source ↗ - News (RSS)seekingalpha·47d ago·Neutral
Trump: Becton Dickinson agrees to invest $3B in US manufacturing, including $1B+ in Nebraska
View source ↗ - News (RSS)investing·47d ago·Neutral
Trump says Becton Dickinson to invest $3 billion in US medical manufacturing
View source ↗ - Newsreuters.com·47d ago·Neutral
Trump says Becton Dickinson to invest $3 billion to expand US medical product manufacturing American medical technology company Becton Dickinson has agreed to invest $3 billion to bring manufacturing of essential medical products to the United States, President Donald Trump said on Monday in a post on the Truth Social website.
View source ↗ - Newszacks.com·52d ago·Positive
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.
View source ↗ - Newszacks.com·55d ago·Neutral
Here's Why You Should Retain BDX Stock in Your Portfolio for Now Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.
View source ↗ - Newsprnewswire.com·62d ago·Neutral
Arthur Hu to Join BD as Chief Information and Digital Officer FRANKLIN LAKES, N.J., Sept. 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Arthur (Art) Hu has been named executive vice president and chief information and digital officer, effective September 30.
View source ↗ - Newsprnewswire.com·69d ago·Neutral
…s, refrigerated medications, and increasingly complex fulfilment needs FRANKLIN LAKES, N.J., Sept. 14, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Fairview Health Services has become the first health system in the United States to deploy the BD Vmax 160, a next generation pharmacy automation robot designed to help health systems manage the increasing complexity of specialty therapies and refrigerated medic…
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·87d ago·Neutral
… to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture.
View source ↗ - Newsprnewswire.com·88d ago·Neutral
BD to Present at Wells Fargo 21st Annual Healthcare Conference FRANKLIN LAKES, N.J., Aug. 26, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m.
View source ↗ - Newszacks.com·94d ago·Negative
BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.
View source ↗ - Newsprnewswire.com·97d ago·Neutral
BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.
View source ↗ - Newszacks.com·101d ago·Neutral
Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.
View source ↗ - Newsseekingalpha.com·101d ago·Positive
Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again.
View source ↗ - Newsprnewswire.com·102d ago·Neutral
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion e
View source ↗ - Newsmarketbeat.com·107d ago·Neutral
Becton, Dickinson and Company Q3 Earnings Call Highlights Becton, Dickinson and Company NYSE: BDX reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company's expectations.
View source ↗
Earnings
Mon, Feb 8(in 3 months)
Consensus estimate $2.35 per share
Typical surprise +2.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$4.15 vs $4.07beat
- Thu, Aug 6$3.23 vs $3.14beat
- Thu, May 7$2.90 vs $2.78beat
- Mon, Feb 9$2.29 vs $2.21beat
- Thu, Nov 6$3.96 vs $3.92beat
- Thu, Aug 7$3.68 vs $3.40beat
Estimates and results for BDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BDX officers and directors.
- Bought
- —
- Sold
- $3.4m
0 trades
22 trades
- Polen Thomas E Jrsold
- Feld Michaelsold
- Feld Michaelsold
- Feld Michaelsold
- Polen Thomas E Jrsold
- Goette Rolandsold
- Feld Michaelsold
- Feld Michaelsold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (28d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Jun 19, 2026 (29d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Apr 6, 2026 (20d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Sell$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Jun 18, 2025 (36d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 10, 2025 (26d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Apr 29, 2025 (21d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Apr 14, 2025 (40d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Sell$1,001 - $15,000
- John Jameshouse · MI10 · disclosed Sep 6, 2024 (2d later)Sell$1,001 - $15,000
- John Jameshouse · MI10 · disclosed Sep 2, 2024 (297d later)Buy$1,001 - $15,000
- Thomas Keanhouse · NJ07 · disclosed Jun 18, 2024 (25d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 5, 2024 (11d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 5, 2024 (15d later)Buy$1,001 - $15,000
- Shelley Moore Capitosenate · WV · disclosed Mar 15, 2024 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
